Document is current
Any future updates will be listed below
-
Authors
Dell’Osso, Bernardo
Albert, Umberto
Carrà, Giuseppe http://orcid.org/0000-0002-6877-6169
Pompili, Maurizio
Nanni, Maria Giulia
Pasquini, Massimo
Poloni, Nicola
Raballo, Andrea
Sambataro, Fabio
Serafini, Gianluca
Viganò, Caterina http://orcid.org/0000-0001-7937-1266
Demyttenaere, Koen
McIntyre, Roger S.
Fiorillo, Andrea
- License Information
-
More Information
Article History
Received: 1 May 2020
Accepted: 20 September 2020
First Online: 12 October 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: In the last three years, Dr Dell’Osso has received lecture honoraria from Angelini, Lundbeck, Janssen, Pfizer, Neuraxpharm, Arcapharma, and Livanova; Dr Serafini received lecture honoraria from Neuraxpharm, Janssen-Cilag, Angelini, and Lundbeck; Dr Viganò has received lecture honoraria from Angelini, Lundbeck/Otsuka, and Gilead. In the last 3 years, Dr. Pompili has received lectures or advisory board honoraria or engaged in clinical trial activities with Angelini, Lundbeck, Janssen, Otsuka, Italfarmaco and Allergan, which are unrelated to this article.Other authors have none to declare.
